WA-EKATA
Ekata , the leader in global digital identity data, today announced its Merchant Onboarding solution to help payment service providers (PSPs), B2B lenders and marketplaces onboard the growing number of micro-merchants and sole proprietors across the globe faster and with more confidence. The lack of commercial track record for these new small businesses makes it difficult for PSPs and lenders to quickly and confidently approve them using traditional methods of risk assessment. Ekata set out to help customers enhance their existing models with risk indicators that show fraud likelihood based on a mix of comprehensive customer data tests and best-practice considerations. By providing unique data that cross-checks the connection between businesses and the individuals behind them, Ekata’s new merchant onboarding solution enables organizations to confidently assess risk at scale, automate onboarding workflows, and reduce time spent in manual review.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210407005320/en/
The global pandemic accelerated an existing trend of individuals establishing their own small businesses. In the U.S. alone there are 30 million small merchants and an additional 40 million individuals who became independent contractors in 2020. Similarly, Europe has 25.1 million small businesses and a growing 33 million sole proprietors . On the tailwinds of this trend, Covid-19 added some additional unexpected fuel: in October 2020, the U.S. Census Bureau published the business-formation statistics for the third quarter of 2020. Third-quarter 2020 business applications rose by 77.4% from June to September .
With this massive growth comes an increasing demand for quick and effective onboarding of these merchants by PSPs and lending institutions. Companies like Stripe, Square, PayPal and others have set a new standard by cutting onboarding times from 2-3 days to just minutes, often threatening the business viability of other PSPs whose processes and risk assessments can’t keep up with their pace. In this intensely competitive market, Ekata’s solution helps PSPs and lenders respond to the increasing expectations for speedier onboarding.
“Merchants today have plenty of options and will quickly turn to another payment service provider if an organization adds too much friction at onboarding or takes too long on approvals ,” says Beth Shulkin, Ekata’s VP of Global Marketing. “This is much more than a customer experience issue for PSPs and lenders; losing the lifetime value of a merchant has real bottom-line impact .”
Ekata’s holistic solution is designed to solve both sides of the flow: automating the onboarding process via APIs and enabling more efficient manual reviews with a SaaS solution. Our API integrates easily with existing rules or machine learning-based risk models, and our SaaS product quickly surfaces correlations between key individual and business identity attributes on easy-to-read dashboards.
Key benefits of the Merchant Onboarding solution include:
- Onboard micro-merchants and sole proprietor businesses with higher confidence: With individual, business, and unique cross-linked signals, Ekata customers can build trusted risk profiles for micro-merchants and sole proprietors that lack the typical track record - verifying information and approving or rejecting applications with confidence.
- Quickly route good customers for automated underwriting: Businesses can shift low-risk merchant applications away from high friction onboarding steps such as supplemental document collection and manual review, towards automated approval, which gets these customers onboard and generating revenue as quickly as possible. They can then focus on high-risk customers that need additional documentation or manual review.
- Reduce time spent in manual review: Businesses can quickly view a key set of individual and business data, reducing the time needed to research data across multiple sources and helping the reviewer make a faster, more efficient, and more accurate decision.
For additional information on Ekata’s Merchant Onboarding API, visit here . To learn more about Ekata’s Merchant Review, visit here .
About Ekata
Ekata provides global identity verification via APIs and a SaaS solution to provide businesses worldwide the ability to link any digital transaction to the human behind it. The Ekata product suite is powered by the Ekata Identity Engine, our proprietary, intellectual property, that uses unique datasets from the Ekata Identity Graph and the Ekata Identity Network that provides identity verification data with consistent results across the globe, in industry-leading response times, to enable businesses around the world like AliPay, Microsoft, Stripe, and Airbnb to fight fraud, reduce false declines, and make accurate risk decisions about their customers faster than the blink of an eye.
Ekata is a trademark of Ekata, Inc. All other trade names, trademarks and registered trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005320/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
